TESARO (NASDAQ: TSRO) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare TESARO to related businesses based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.
Earnings and Valuation
This table compares TESARO and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|TESARO||$44.82 million||-$387.47 million||-9.72|
|TESARO Competitors||$284.28 million||$33.78 million||84.15|
This is a summary of current ratings and price targets for TESARO and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TESARO currently has a consensus target price of $158.57, suggesting a potential upside of 93.33%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.32%. Given TESARO’s higher probable upside, analysts plainly believe TESARO is more favorable than its peers.
Volatility and Risk
TESARO has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, TESARO’s peers have a beta of 6.08, meaning that their average share price is 508% more volatile than the S&P 500.
This table compares TESARO and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 34.6% of TESARO shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
TESARO peers beat TESARO on 8 of the 12 factors compared.
TESARO Company Profile
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.